Dana-farber-cancer Institute Inc.

Harvard College

Novartis Ag

The General Hospital Corporation

Children's Medical Center Corporation

Immutep S.a.s.

The General Hospital Corporation D/b/a Massachusetts General Hospital

Glenn Dranoff

Kai W Wucherpfennig

David J Mooney

Omar Abdel-Rahman Ali

F Stephen Hodi

Christopher Harvey

Kenneth F May, Jr

Gordon James Freeman

Nir Hacohen

Harvey I Cantor

Christopher Sean Straub

Leigh Zawel

Gerhard Johann Frey

Hwai Wen Chang

Jennifer Brogdon

Arlene Helen Sharpe

Walter A Blattler

Jennifer Marie Mataraza

Kwok-kin Wong

Boris Engels

Catherine Anne Sabatos-Peyton

Bettina Franz

Donald Raymond Shaffer

Lu Huang

Chonghui Zhang

Tony Fleming

Brian Walter Granda

Carla Guimaraes

Aida Abujoub

Connie Hong

Frédéric Triebel

John Blankenship

Brian Holmberg

Peter Hammerman

John Scott Cameron

Brant G Firestone

Michael Dougan

Matthew Vanneman

Diana Alvarez Arias

Penghui Zhou

Silke Gillessen

S Brian Wilson

Ryan Sullivan

Dexiu Bu

Joseph A Mollick

Carla F Kim

Deborah A Knee

Fei Wang

Xu Zhu

Michael R Greene

Sanela Bilic

Daniela Cipolletta

Masahisa Jinushi

Louise Treanor

Andrew Price

Joni Waiee Lam

Akash Sohoni

Anniesha Hack

Serena De Vita

Hyungwook Lim

Elizabeth Dorothy Pratico

Olja Kodrasi

Attilio Bondanza

Omar Ali

Andrew Marc Stein

Chunxiao Xu

Christine F Brainson

Jan Schmollinger

Gordon Freeman

Christopher S Straub

Danny Roland Howard

Chrystlle Brignone

Johann Gerhard

The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

Chimeric antigen receptors and uses thereof

The present invention comprises compositions, methods, and devices for enhancing an endogenous immune response against a cancer. Devices and methods provide therapeutic immunity to subjects against cancer.

Combination vaccine devices and methods of killing cancer cells

Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.

NKG2D-IG fusion protein for cancer immunotherapy

The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.

Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response

The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.

Methods and compositions for reducing immunosuppression by tumor cells

The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.

Immunomodulation by IAP inhibitors

Methods and compositions for reducing immunosupression by tumor cells

Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.

NKG2D-fc for immunotherapy

Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Antibody molecules to PD-L1 and methods of treating cancer

The present disclosure provides, in part, compositions comprising peptides that immunospecifically bind to a defined binding partner, such as MHC class I polypeptide-related sequence A (MICA), or an epitope thereon. In some embodiments, the peptides comprise one or more complementarity determining regions relating to the complementarity regions shown in Table 1. The disclosure also provides methods of treating cancer in a subject using the compositions disclosed herein, and methods of isolating human antibodies from cancer patients following immunotherapy.

Therapeutic peptides

The present disclosure provides, in part, compositions comprising peptides immuno specifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors; as well as pharmaceutical compositions that comprise such molecules and methods of use thereof.

Compositions and methods of use for augmented immune response and cancer therapy

Growing community of inventors

Sudbury, MA, United States of America

Glenn Dranoff